To confirm that selective HDAC1/2 inhibition phenocopies the effects seen with the global HDAC inhibitor we tested the combination treatment of gamitrinib and romidepsin in established and patient derived GBM cells as well (Figure 2C and Figure S3C–F). This evidence concerns the gene HDAC1 and glioblastoma.